1KA Stock Chart & Stats
€24.20
€0.40(1.69%)
At close: 4:00 PM EDT
€24.20
€0.40(1.69%)
Day’s Range― - ―
52-Week Range€10.20 - €27.00
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€1.15B
Enterprise Value€1.43B
Total Cash (Recent Filing)€362.65M
Total Debt (Recent Filing)€360.00K
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Nov 05, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding68,642,290
10 Day Avg. Volume7
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio-3.01
Price to Book (P/B)2.77
Price to Sales (P/S)0.00
P/FCF Ratio-17.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.68Price Target Upside59.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetExtremely low leverage and a substantial equity base give GH Research flexibility to continue funding clinical development without significant debt service pressure. This strengthens resilience during the pre-commercial period and provides a broader financial runway for advancing its pipeline.
Focused Clinical PipelineThe company is concentrated on a clearly defined therapeutic platform addressing psychiatric and neurological disorders, with GH001 already in clinical testing. A rapid-acting, inhaled approach could support differentiated product positioning if clinical development and regulatory progress continue.
External Scientific ValidationPresentation of trial data at a major neuropsychopharmacology meeting, alongside involvement from prominent researchers, can broaden scientific visibility and support credibility with clinicians and potential partners. It also creates a durable opportunity to strengthen positioning in rapid-acting psychiatric treatments.
Bears Say
Pre-revenue Business ModelGH Research has not begun generating product revenue, so its financial profile remains dependent on successful clinical development and eventual regulatory approval. Until commercialization occurs, there is no demonstrated revenue base to absorb operating costs or provide internal funding for expansion.
Widening Net LossesLosses have expanded materially as research and operating expenses rise ahead of commercialization. This persistent cost growth reduces equity returns and increases the amount of capital required to sustain development, leaving profitability dependent on future clinical and regulatory success.
Persistent Cash BurnSustained negative operating and free cash flow means GH Research is consuming capital rather than funding operations internally. Continued investment in trials may be necessary, but the cash deficit can ultimately require additional financing and may limit strategic flexibility if development spending remains elevated.
GH Research News
1KA FAQ
What was GH Research’s price range in the past 12 months?
GH Research lowest stock price was €10.20 and its highest was €27.00 in the past 12 months.
What is GH Research’s market cap?
GH Research’s market cap is €1.15B.
When is GH Research’s upcoming earnings report date?
GH Research’s upcoming earnings report date is Nov 05, 2026 which is in 19 days.
How were GH Research’s earnings last quarter?
GH Research released its earnings results on Aug 06, 2026. The company reported -€0.205 earnings per share for the quarter, beating the consensus estimate of -€0.271 by €0.066.
Is GH Research overvalued?
According to Wall Street analysts GH Research’s price is currently Undervalued.
Does GH Research pay dividends?
GH Research does not currently pay dividends.
What is GH Research’s EPS estimate?
GH Research’s EPS estimate is -0.28.
How many shares outstanding does GH Research have?
GH Research has 68,642,290 shares outstanding.
What happened to GH Research’s price movement after its last earnings report?
GH Research reported an EPS of -€0.205 in its last earnings report, beating expectations of -€0.271. Following the earnings report the stock price went up 3.252%.
Which hedge fund is a major shareholder of GH Research?
Currently, no hedge funds are holding shares in DE:1KA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GH Research Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€38.68 (59.82% Upside)
€38.68 (59.82% Upside)
Blogger Sentiment
Bullish
DE:1KA Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.33%
12-Months-Change
Fundamentals
Return on Equity
-20.86%
Trailing 12-Months
Asset Growth
18.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GH Research
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
1KA Stock 12 Month Forecast
Average Price Target
€38.68
▲(59.82% Upside)
Technical Analysis
COMPASS Pathways
―
Bright Minds Biosciences
―
Alto Neuroscience, Inc.
―
LB Pharmaceuticals, Inc.
―
Seaport Therapeutics, Inc.
―